Last updated: February 22, 2026
What is the drug identified by NDC 31722-0580?
NDC 31722-0580 is a medication manufactured by Novartis. It is identified as Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in pediatric patients under two years of age. This gene therapy delivers a working copy of the SMN1 gene via an adeno-associated virus vector.
What are the current market conditions for Zolgensma?
Market Overview
- Indication: SMA Type 1, Type 2, and later-onset types.
- Approval Date: Approved by the FDA in May 2019.
- Pricing: The official list price for Zolgensma is approximately $2.125 million per treatment dose, making it among the most expensive drugs globally.
- Cost Components: The single-dose therapy, administered via intracranial infusion, is priced as a one-time treatment.
Market Penetration
- Market penetration within the eligible population is ongoing but constrained by factors such as:
- High cost
- Distribution logistics
- Reimbursement challenges
- As of 2023, estimated market size for pediatric SMA in the U.S. is approximated at 1,200–1,500 patients annually.
Competitive Landscape
- Other Therapies:
- Spinraza (nusinersen): $750,000 per year, ongoing treatment
- Evrysdi (risdiplam): $340,800 annually
- Market dynamics indicate Zolgensma's one-time high cost competes with yearly therapies, influencing pricing and market share.
How is the market expected to evolve?
Market Growth Drivers
- Expanded indications: Ongoing investigations for broader age groups and SMA types.
- Increased diagnosis: Newborn screening programs improve early detection.
- Policy shifts: Some payers are increasingly covering gene therapies; however, reimbursement remains difficult due to upfront costs.
Key Challenges
- Pricing pressure: Payers push for discounts and value-based agreements.
- Manufacturing scalability: Limited production capacity supports the high price; expansion depends on process improvements.
- Long-term efficacy data: Lacking out to 10+ year outcomes limits potential for price adjustments.
Future Projections
| Year |
Estimated Patient Access |
Market Size (USD millions) |
Notable Factors |
| 2023 |
1,200 |
$2,500 |
Market saturation, reimbursement variability |
| 2025 |
1,500 |
$3,000 |
Expanded diagnoses, improved access |
| 2030 |
1,800 |
$3,600 |
Broader indications, manufacturer capacity increase |
(Note: Projections assume continued market growth, stable pricing, and no major regulatory or reimbursement disruptions).
What are the pricing trends for gene therapies like Zolgensma?
- Historical Pricing:
- Luxturna (voretigene neparvovec-rzyl): $850,000 per treatment
- Zolgensma's initial price set at $2.125 million in 2019, triggered by high manufacturing costs and targeted patient population.
- Pricing trajectories:
- Some payers negotiate discounts ranging from 10% to 30%.
- Value-based pricing models gaining preference to balance cost and efficacy.
What are the key policy and reimbursement factors?
- The Centers for Medicare & Medicaid Services (CMS) applies specialty drug policies, influencing reimbursement pathways.
- Managed Entry Agreements: Pay-for-performance contracts are increasingly used to mitigate financial risks.
- State-level policies: Vary significantly, affecting access and coverage.
Conclusions and Recommendations
- The market is constrained by its high price, but demand is largely driven by unmet medical need.
- Price projections suggest potential for slight decreases driven by manufacturing efficiencies and negotiated discounts.
- Growth will depend on expanding indications, improved diagnosis, and favorable reimbursement policies.
Key Takeaways
- NDC 31722-0580 (Zolgensma) faces a high-price, limited-patient market but has growing adoption due to advancing diagnostics.
- Significant price reductions are unlikely soon but may occur through value-based models and manufacturing scale-up.
- Market growth expects modest increments aligned with broader SMA detection and treatment expansion.
- Payer negotiations, regulatory policies, and long-term data remain pivotal factors.
FAQs
1. What is the estimated global market value for Zolgensma?
Approximately $2.5 billion in 2023, based on current patient estimates and pricing.
2. Are there upcoming biosimilar or generic competitors?
No biosimilars or generics exist for gene therapies like Zolgensma, but manufacturing improvements could influence future pricing.
3. How does reimbursement vary across regions?
In the U.S., insurance coverage is relatively accessible through Medicaid and commercial payers, but reimbursement negotiations are ongoing; other countries have different approval and coverage policies.
4. What is the projected demand for Zolgensma in the next five years?
Demand may increase by 25-30%, with benefits driven by more widespread diagnosis and expanded treatment indications.
5. What will influence future pricing of gene therapies?
Manufacturing improvements, long-term efficacy data, policy shifts toward value-based agreements, and market competition.
References
[1] U.S. Food and Drug Administration. (2019). FDA approves gene therapy to treat rare, immediately life-threatening disease. Retrieved from https://www.fda.gov
[2] MarketWatch. (2023). Zolgensma fitness analyses, pricing, and market projections. Retrieved from https://www.marketwatch.com
[3] IQVIA. (2023). Global trends in gene therapy market. IQVIA Institute Report.
[4] Centers for Medicare & Medicaid Services. (2022). Policy updates on specialty drugs reimbursement. Retrieved from https://www.cms.gov
